FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before Surgery

FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before Surgery is a phase 2, interventional study registered as NCT06780787 by City of Hope Medical Center, with a registry enrolment figure of 26 participants, started 2025-05-20 and due to reach its primary completion in 2027-11-05. Interventions recorded: Balstilimab; Biospecimen Collection; Botensilimab; Capecitabine; Computed Tomography; Digital Rectal Examination; Endoscopic Biopsy; Fluorouracil; Leucovorin Calcium; Magnetic Resonance Imaging; Oxaliplatin; Radiation Therapy; Sigmoidoscopy. Conditions listed: Rectal Adenocarcinoma; Stage IIA Rectal Cancer AJCC v8; Stage III Rectal Cancer AJCC v8. Primary outcome: Complete clinical response (cCR) rate. Colorectal eligibility wording from the registry: "* Histologically confirmed adenocarcinoma of the rectum". Sites: United States. No results are recorded here; the registry entry is the source.